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ABSTRACT Recent studies of long-term potentiation
(LTP) in the CAl region ofthe hippocampus have demonstrated
that nitric oxide (NO) may be involved in some forms ofLTP and
have suggested that postsynaptically generated NO is a candi-
date to act as a retrograde messenger. However, the molecular
target(s) of NO in LTP remain to be elucidated. The present
study examined whether either of two potential NO targets, a
soluble guanylyl cyclase or an ADP-ribosyltansferase (ADPRT;
EC 2.4.2.31) plays a role in LTP. The application ofmembrane-
permeant analogs of cGMP did not produce any long-lasting
alterations in synaptic strength. In addition, application of a
cGMP-dependent protein kinase inhibitor did not prevent LTP.
We found that the CAl tissue from hippocampus an
ADPRT activity that is dramatically stimulated by NO and
attenuated by two different inhibitors ofmono-ADPRT activity,
phyiloquinone and nicotinamide. The extracellular application
of these same inhibitors prevented LTP. Postsynaptic injection
of nicotinamide failed to attenuate LTP, su Igg n that the
critical site of ADPRT activity resides at a nonpostsynaptic
locus. These results suggest that ADP-ribosylation plays a role in
LTP and are consistent with the idea that an ADPRT may be a
target of NO action.
Long-term potentiation (LTP) in the CA1 region of the
hippocampus is an extensively studied form of synaptic
plasticity which is initiated by a series ofpostsynaptic events
including Ca2+ influx through N-methyl-D-aspartate
(NMDA) receptor channels (1) but may be maintained, at
least in part, by presynaptic mechanisms (1, 2). With standard
LTP induction protocols at room temperature (3-5) and with
standard (6-8) or weak (9-11) induction protocols at warmer
temperatures (but see refs. 5 and 12) the diffusible messenger
nitric oxide (NO) is required for LTP production, suggesting
that NO may mediate the retrograde communication (2, 13,
14) necessary to bring about a presynaptic component ofLTP
expression. However, the location and identity of the mo-
lecular target(s) of NO are still unknown.
The major target of NO in many areas appears to be a
guanylyl cyclase (15-18). In the hippocampus, high-frequen-
cy stimulation can produce rises in cGMP that are blocked by
NO synthase inhibitors (10). In addition, membrane-
permeant analogs of cGMP have been reported to enhance
hippocampal synaptic transmission (19) and reduce the inhi-
bition of LTP produced by NO synthase inhibitors (4).
ADP-ribosyltransferases (ADPRTs; EC 2.4.2.31) are en-
zymes that covalently modify their substrate proteins by
attaching ADP-ribose moiety(s) from NAD+ or NADP+ to
specific residues. Poly-ADPRTs, which attach multiple ADP-
ribose moieties to their substrates, are primarily nuclear
enzymes (20). In contrast, mono-ADPRTs usually attach a
single ADP-ribose moiety and possess cytosolic activity (20).
Several endogenous mammalian mono-ADPRTs have been
described (21-25), but the precise cellular functions of these
enzymes remain poorly understood. Early studies suggested
that NO-donating compounds can stimulate the ADP-
ribosylation of proteins (26, 27), including glyceraldehyde-3'-
phosphate dehydrogenase (GAPDH). Although the early stud-
ies suggested that the modification ofGAPDH was mediated
by an endogenous ADPRT, subsequent studies have revealed
that the modification is mediated by an autocatalytic mecha-
nism (25, 28-31). NO may also stimulate the auto-ADP-
ribosylation ofthe poly-ADPRT (32, 33). In addition, there are
numerous reports that NO can stimulate enzyme-mediated
ADP-ribosylation of several neuronal proteins (34-38). In
addition, quite recently Duman et al. (39) have shown that
when in vitro assays are performed after LTP induction, less
NO-stimulated ADP-ribosylation can be produced in LTP-
induced slices than in control slices, suggesting that NO-
stimulated ADP-ribosylation may occur during LTP induc-
tion. To elucidate the potential mechanisms of action of NO
during LTP, we have performed experiments to test the
involvement of guanylyl cyclase and/or ADPRT activity.
MATERIALS AND METHODS
Electrophysiology. Hippocampal slices were prepared from
male Sprague-Dawley rats, 150-250 g, as described (3).
Slices were submerged in a stream of ACSF (119 mM
NaCl/2.5 mM KCl/1.3 mM MgSO4/2.5 mM CaCl2/1.0 mM
NaH2PO4/26.2 mM NaHCO3/11.0 mM glucose) maintained
at 250C and gased with 95% 02/5% CO2. Field or intracellular
excitatory postsynaptic potentials or currents (EPSPs or
EPSCs) measured in stratum radiatum or in CA1 pyramidal
cells, respectively, were evoked by stimulation of the Schaf-
fer collateral-commissural afferents (2 or 4 per min).
8-Bromo- or dibutyryl-cGMP (100 /uM or 1 mM) and AP5 (50
pM) were applied to slices for at least 20-30 min prior to LTP
induction. All other inhibitors were applied to slices for 45-90
min. 8-Bromo- and dibutyryl-cGMP, H-8, nicotinamide (Nic)
(Sigma), and AP5 (Research Biochemicals, Natick, MA)
were initially dissolved in water; phylloquinone (Phyl) and
benzamide (Sigma) were dissolved in dimethyl sulfoxide.
Phyl, a fat-soluble compound, was likely applied at -%50% of
the stated concentration, due to difficulties dissolving it at
high concentration in dimethyl sulfoxide. Extracellular re-
cording electrodes were filled with 3 M NaCl; intracellular
recording electrodes were filled with 2 M KMeSO4 or 2 M
cesium acetate including Nic (500mM). Whole-cell electrode
internal solutions consisted of 100mM cesium gluconate, 0.6
mM EGTA, 5 mM MgCl, 2 mM ATP, 0.3 mM GTP, 40 mM
Hepes, and 1 mM QX-314. NMDA-mediated whole-cell
EPSCs or extracellular field potentials were recorded from
Abbreviations: LTP, long-term potentiation; NMDA, N-methyl-D-
aspartate; ADPRT, ADP-ribosyltransferase; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase; EPSP, excitatory postsynaptic
potential; IPSP, inhibitory postsynaptic potential; EPSC, excitatory
postsynaptic current; Nic, nicotinamide; Phyl, phylloquinone;
SIN-1, 3-morpholinosydnonimine.
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CA1 pyramidal neurons in the presence of 10 gM 6-cyano-
7-nitroquinoxaline (CNQX), 10 ,uM glycine, and 50 gM
picrotoxin. Tetanic stimulation was delivered at the test
intensity in 1-s trains at 100 Hz, with one to four trains 15 or
30 s apart. Pairing was accomplished by sustained depolar-
ization of the neuron by dc injection in conjunction with
low-frequency (1-Hz) stimulation of the test pathway for
30-45 s. We analyzed the initial slope ofthe field EPSP or the
amplitude of the intracellular EPSP or whole-cell EPSC.
Ensemble average plots represent group means of each
EPSP, across experiments, aligned with respect to the time
of acquisition relative to the tetanic stimulation. Each indi-
vidual experiment was normalized with respect to the mean
value of its EPSP in the 50 responses that preceded the
tetanus. Statistical comparisons were made with the Student
t test, performed on raw data.
Inhibitors. In hen heterophils, Phyl is reported to be a more
potent inhibitor of the mono-ADPRT (IC50 = 1.9 juM) than
the poly-ADPRT (IC50 = 520 1uM) (40, 41). Nic inhibits both
the mono- (IC50 = 3400 ,uM) and poly-ADPRT (IC50 = 31 ,uM)
(41). Benzamide is a more potent inhibitor of the poly-
ADPRT (IC50 = 3.3 1LM) than the mono-ADPRT (IC5o = 4100
ILM) (41). The Ki values of H-8 for cGMP-dependent protein
kinases, cAMP-dependent protein kinases, and protein ki-
nase C (PKC) are 0.48 ,uM, 1.5 ,uM, and 15 ,uM, respectively
(42). We also attempted to use a more potent and selective
inhibitor of cGMP-dependent protein kinase, Rp cGMP (Bi-
olog, La Jolla, CA), but we found that this compound induces
a persistent depression of synaptic transmission.
ADP-Ribosylation. The CAl regions of hippocampi were
isolated from 150- to 250-g male Sprague-Dawley rats and
homogenized in 100 mM Hepes containing 0.5 mM EDTA
and a cocktail of protease inhibitors including aprotinin,
leupeptin, chymostatin, and pepstatin A, each at 10 ng/ml
and 100 ,M phenylmethanesulfonyl fluoride. The resulting
homogenate was aliquoted, frozen on dry ice, and stored over
liquid nitrogen. Protein was measured by the Bradford assay.
ADP-ribosylation was carried out with minor modifications
of the procedures of Brune and Lapetina (26, 27). The
reaction was performed in a final volume of 65 ,ul containing
100mM Hepes buffer (pH 7.5), 1 ,uM unlabeled NAD+, 5 uCi
(1 Ci = 37 GBq) of[32P]NAD+, 7.5mM dithiothreitol, and 100
pg of CA1 homogenate protein. CNBr-activated Sepharose
beads were linked to arginine or cysteine by incubation for 3
hr at 4°C with 0.2 M L-arginine or L-cysteine and then washed
and resuspended in a Hepes buffer. Twenty microliters of
arginine- or cysteine-linked beads was added to a reaction
mixture identical to that described above. The mixture was
incubated at 37°C for 30 min on a rotator, washed with 500
mM NaCl/10%o (vol/vol) glycerol, and then spun 10 s at
10,000 x g. Individual reactions were conducted in the
presence or absence of hippocampal homogenate to examine
the dependence of 32p incorporation on exogenous enzyme.
The NO donor 3-morpholinosydnonimine (SIN-1; 500 pM)
was also added alone or in the presence of the ADPRT
inhibitors Phyl or Nic. 32p incorporation (cpm) was measured
with a scintillation counter.
RESULTS
Tests of the Role of cGMP. Previous work indicates that an
NO-sensitive guanylyl cyclase activity is present in the hip-
pocampus. To examine the possibility that cGMP may par-
ticipate in LTP production, phosphodiesterase-resistant mem-
brane-permeant analogs of cGMP (dibutyryl- or 8-bromo-
cGMP; 100 ,uM or 1 mM) were applied extracellularly while
the magnitude of the field EPSP was monitored. As has been
reported by others (4, 19), cGMP analogs alone failed to induce
any enhancement of synaptic transmission 1101.6% ± 3.8%
(mean percent of baseline ± SEM), 30 min after application]
(Fig. 1). Tetanic stimulation delivered to presynaptic afferents
in the presence of the cGMP analog and the NMDA receptor
antagonist AP5 (50 pM) also failed to produce any synaptic
enhancement, although the same tetanic stimulus delivered
after the washout ofAP5 and the cGMP analog resulted in LTP
(Fig. 1 A and B). To assess the involvement of a cGMP-
dependent protein kinase (cGMP-PK) we applied the general
protein kinase inhibitor H-8, which, at low concentrations, is
most efficacious in inhibiting cyclic nucleotide-dependent pro-
tein kinases (42). H-8 (10 ,uM) did not affect the magnitude or
the time course of the potentiation elicited by tetanic stimu-
lation, suggesting that cGMP-PK activity is not required for
LTP production (control, 139.7% ± 13.5%; H-8, 152.9% ±
12.5%; n = 9) (Fig. 1 C and D).
NO-Stimulated ADP-Ribosylation. To test if cells in region
CA1 of the hippocampus possess NO-stimulated ADPRT
activity, we conducted an in vitro assay which examined the
ability of CA1 hippocampal tissue to promote the ADP-
ribosylation of amino acid residues. Previous studies (43, 44)
have shown that isolated amino acids can serve as exogenous
ADP-ribose acceptors for purified ADPRTs. In a similar
manner, we linked either arginine or cysteine [two common
acceptors for ADP-ribose in mono-ADP-ribosylation reac-
tions (20)] to CNBr-activated Sepharose beads and then
added the beads to a standard ADP-ribosylation mixture
containing [32P]NAD+. Bead-linked amino acids were then
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FIG. 1. (A and B) Extracellular application
of cGMP analogs does not induce synaptic en-
hancement. (A) Field EPSP recording of hippo-
campal slice exposed to tetanic stimulation (ar-
rows) in APS alone, in AP5 + dibutyryl-cGMP,
and after washing with ACSF. (B) Summary
data. No significant LTP was produced in AP5
alone, or in AP5 + 100 uM (n = 4) or 1 mM (n
= 3) dibutyryl-cGMP; however, LTP was ob-
tained in the same slices after washing with
ACSF (n = 7; P < 0.01) as measured 20 min
(AP5 + cGMP) or 1 hr (wash) after tetanus. (C
and D) H-8, a cGMP-dependent protein kinase
inhibitor, does not block LTP. Ensemble aver-
ages show a significant amount ofpotentiation in
both control (C) (P < 0.05) and H-8-treated (D)
(P < 0.01) pathways.
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separated from the reaction mixture by a series of centrifu-
gations and also subjected to high-salt washes to remove any
ionically bound molecules.
In the absence of hippocampal tissue, a small amount of
background incorporation of 32p was observed on the beads;
this background activity was not affected by the addition of
the NO donor SIN-1 at 500 ,uM (Fig. 2). However, the
addition of CA1 homogenate to the ADP-ribosylation reac-
tion mixture significantly stimulated the ADP-ribosylation of
both arginine and cysteine (Fig. 2). This tissue-stimulated
ADP-ribosylation was enhanced severalfold by the addition
of SIN-1. It is unlikely that the observed ADP-ribosylation is
nonenzymatic, since arginine does not undergo this type of
reaction (45) and there are no amino groups available for
nonenzymatic attachment on cysteine bound to beads. In
addition, the NAD glycohydrolase inhibitor isoniazid (20
mM) produced no inhibition of the NO-stimulated ADP-
ribosylation (n = 4; data not shown). In contrast, the mono-
ADPRT inhibitors Phyl (100 gM) and Nic (10 mM) signifi-
cantly attenuated the NO-induced enhancement of the ADP-
ribosylation of arginine and, to a lesser extent, reduced the
ADP-ribosylation of cysteine (Fig. 2). The different sensitiv-
ities to the ADPRT inhibitors exhibited by the arginine and
cysteine are consistent with the existence of distinct classes
ofendogenous ADPRTs which preferentially modify arginine
or cysteine residues (20, 24).
It has been reported that NO stimulates the automodifica-
tion of GAPDH, rather than stimulating the activity of
endogenous ADPRT (28-30). To test if the NO-stimulated
ADP-ribosylation observed in the presence of CA1 tissue
could be accounted for by GAPDH present in the hippocam-
pal homogenate, we added purified GAPDH and NO to
reaction mixtures in the absence of CA1 tissue. The addition
of GAPDH and NO failed to promote the ADP-ribosylation
of either arginine or cysteine (Fig. 2). Thus, these data
indicate that under these particular experimental conditions
NO does not stimulate GAPDH-mediated ADP-ribosylation
of exogenous amino acids.
Extracellular Application of ADPRT Inhibitors. To test
whether the activity of an ADPRT participates in LTP
production we utilized the same ADPRT inhibitors that
attenuated the endogenous hippocampal ADPRT activity
(Fig. 2). In each experiment, two afferent pathways in the
same slice were utilized to examine both control and inhib-
itor-treated potentiation. Phyl was also a very effective
blocker of LTP, at a concentration (100 gM) well below the
IC50 for inhibition of the poly-ADPRT reported in other tissue
[control potentiation, 161.0% ± 18.4%; Phyl, 111.0o ± 6.4%
(mean percent of baseline ± SEM)] (Fig. 3 A and D). The
ADPRT inhibitor Nic also blocked LTP, in a dose-dependent
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FIG. 3. Extracellular application of mono-ADPRT inhibitors
prevents tetanus-induced LTP (arrowheads) of the field EPSP. The
Insets above each ensemble average show two representative field
EPSPs from a slice bathed in control ACSF (A-C Left) or in a second
afferent pathway after inhibitor application (A-C Right), recorded 10
min before and 60 min after tetanic stimulation. (A-C) Ensemble
averages for control and Phyl (A), control and Nic (B), and control
and benzamide (C) experiments. For A-C a significant amount of
potentiation was observed in all control (P < 0.01) and benzamide-
treated (P < 0.05) pathways, but not in pathways treated with Nic or
Phyl. (D) Summary. Asterisks indicate that Phyl- and Nic-treated
pathways exhibited significantly less LTP than their controls (P <
0.05 and P < 0.01, respectively).
manner: 10 mM Nic was most effective (Fig. 3 B and D), 1
mM Nic was less effective, and 200 gM was ineffective
[control (n = 9), 150.6% ± 9.3%; 10 mM Nic (n = 9), 97.0%
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6.0%o; 1 mM Nic (n = 9), 109.1% ± 8.7%; 200 ,uM Nic (n
= 8), 143.1% ± 7.3%]. The observed dose-response profile
fits with the interpretation that Nic is working by inhibiting
a mono- rather than a poly-ADPRT. Nic (1-5 mM) also
blocked LTP when experiments were conducted at 30'C
rather than room temperature [91.7% ± 11.7% (n = 6)]. To
directly assess the potential involvement of a poly-ADPRT
we used the poly-ADPRT inhibitor benzamide at 100 jiM (40,
41). In contrast to the block of LTP observed with Phyl and
Nic, benzamide did not prevent tetanus-induced enhance-
ment of synaptic transmission (control, 161.0%, ± 9.1%;
benzamide, 167.1% ± 18.6%) (Fig. 3 C and D). Taken
together, these data suggest that mono- rather than poly-
ADPRT activity is necessary for the induction of LTP.
A blockade of LTP was observed with two different
ADPRT inhibitors (Phyl and Nic) with distinct chemical
structures, arguing against a nonspecific pharmacological
effect being responsible for the prevention of LTP. As
illustrated in Fig. 4A, neither of the ADPRT inhibitors that
were effective in blocking LTP had any significant effect on
basal excitatory synaptic transmission. In addition, neither
inhibitor had any significant effect on either the inhibitory
postsynaptic potential (IPSP) recorded in pyramidal neurons
(mean of control IPSP ± SEM: Phyl, 95.7% + 1.3%, n = 3;
Nic, 91.8% ± 5.4%, n = 4) (Fig. 4B) or on the NMDA-
mediated component of the EPSC measured with whole-cell
recording (mean of control current ± SEM: Phyl, 101.3% +
9.4; Nic, 96.8% ± 8.7). Fig. 4 also illustrates that the NO
synthase inhibitor L-methylarginine, previously reported to
block LTP, has no effect on the amplitude of the NMDA
current. In addition, L-nitroarginine (10-100 &M) does not
affect the pharmacologically isolated NMDA-receptor-
mediated extracellular field potential (data not shown). The
inability of Phyl and Nic to alter basal excitatory, inhibitory,
and NMDA-mediated synaptic transmission is consistent
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with the interpretation that these drugs block LTP by inter-
fering with the ADPRT activity.
Postsynaptic Injection of ADPRT Inhibitor. To ascertain
whether postsynaptic ADPRT activity is important for LTP,
Nic was injected directly into an individual postsynaptic CA1
pyramidal neuron through the intracellular recording micro-
electrode (Fig. 5). In contrast to the blockade of LTP
observed when Nic was applied in the bath, intracellular
postsynaptic Nic did not prevent pairing- or tetanus-induced
synaptic enhancement of the intracellular EPSP [200.8% ±
26.1% or 214.0o ± 18.7%, 1 hr after pairing (n = 4; data not
shown) or tetanus, respectively] (Fig. SB). However, tetanus-
induced LTP of a second afferent pathway in the same slice
was blocked after Nic (5-10 mM) was added to the bath
(90.1% ± 4.7%) (Fig. 5 B and C). The possibility that
postsynaptically introduced Nic failed to reach sufficient
concentrations in the dendrites cannot be ruled out at this
time. However, it is attractive to suggest that Nic's potency
in preventing LTP when applied in the bath may be attributed
to inhibition of ADPRT activity at a site other than the
postsynaptic cell, perhaps the presynaptic nerve terminal, or
another compartment such as glial cells.
Induction vs. Maintenance. In several experiments, Nic or
Phyl was added to the bath after LTP induction to examine
whether continuous ADPRT activity is necessary to maintain
potentiation. As illustrated in Fig. 5, bath application of Nic
after induction of LTP produced little decline in the field or
intracellular EPSP. Potentiated pathways exposed to Nic or
Phyl beginning 10-20 min after tetanus exhibited 11.6% ±
3.0%o (n = 15) or 3.9o ± 6.7% (n = 8) decline, respectively,
measured 40-50 min after the initial application of the inhib-
itor. Potentiated pathways not exposed to an inhibitor ex-
hibited 12.2% ± 3.4% (n = 10) decline. Thus, inhibition of
ADPRT activity after LTP induction does not affect estab-
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FIG. 5. Injection of Nic into the postsynaptic cell does not block
LTP. (A) Schematic diagram. Two stimulating electrodes, an extra-
cellular recording electrode (B2), and an intracellular microelectrode
containing 500 mM Nic (Bi) were placed as shown in a hippocampal
slice. (B and C) Nic was injected into the postsynaptic cell prior to
tetanic stimulation of one pathway and subsequently applied in the
bath prior to tetanic stimulation ofa second pathway. (B) Intracellular
EPSP amplitudes elicited by stimulation of two independent (Upper
and Lower) afferent pathways. (C) Field EPSP slopes for stimulation
oftwo independent (Upper and Lower) populations of afferent fibers.
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lished LTP, suggesting that ADPRT activity is important only
during a window of time surrounding LTP induction.
DISCUSSION
The inability of membrane-permeant cGMP analogs to pro-
duce potentiation and the inability of H-8 to attenuate LTP
suggests that cGMP-dependent processes are neither neces-
sary nor sufficient for LTP production. It should be noted that
our results differ from the recently published studies of Zhou
et al. (19). There are several differences in the experimental
protocols used that could account for the different results
obtained, including the type of chamber used (submerged vs.
interface), the recording temperature (22-25TC vs. 30°(), and
the stimulation frequency (0.15-0.33 Hz vs. 0.02 Hz). We have
not been able to directly address the role of cGMP, since
available inhibitors of guanylyl cyclase-e.g., methylene blue
and LY83583-depress synaptic transmission (unpublished
observations) or inhibit NO production (46), respectively.
The experiments performed with arginine and cysteine
provide simple and clear evidence that the CA1 region of the
hippocampus possesses an ADPRT activity that can be
significantly enhanced by NO and attenuated by inhibitors of
mono-ADP-ribosylation. These data support observations
from other laboratories that NO can stimulate the activity of
endogenous cellular ADPRTs (34, 35). The electrophysiolog-
ical data provide evidence that ADPRT activity may be an
important step in LTP production. Two chemically distinct
ADPRT inhibitors prevented LTP, without affecting basal
excitatory or inhibitory synaptic transmission or affecting the
magnitude of the NMDA-mediated whole-cell currents. Nat-
urally, our interpretation ofthese data relies on the specificity
of the inhibitors we have used; in future experiments it will
be necessary to examine directly whether ADP-ribosylation
is involved in LTP.
It is interesting to speculate on potential mechanisms that
involve ADPRT activity in the presynaptic terminal. Com-
mon targets for mono-ADP-ribosylation include GTP-binding
proteins (20, 24, 34, 47) and the growth-associated protein
GAP-43/B-50 (48). Recent reports indicate that NO can
stimulate neurotransmitter release fom isolated hippocam-
pal nerve terminals (45, 49). Since both G proteins and
GAP-43 may modulate exocytosis (50, 51), the regulation of
these protein(s) by NO-stimulated ADP-ribosylation could
potentially lead to increases in neurotransmitter release that
may function as a mechanism of LTP expression.
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